CHATTANOOGA, Tenn.–(BUSINESS WIRE)–#Starmount–A longtime leader in employee benefits, Unum (NYSE:UNM) has entered a new arena with the launch of Unum Dental and Unum Vision.
Category: Business
Heidelberg Engineering and Gauss Medical Corporation Establish an Ophthalmic Healthcare IT Joint Venture in China
HEIDELBERG, Germany–(BUSINESS WIRE)–Heidelberg Engineering and Gauss Medical Corporation Establish an Ophthalmic Healthcare IT Joint Venture in China
First US Service Members Treated with the Only FDA-Approved Cross-Linking Procedure in the U.S.
WALTHAM, Mass.–(BUSINESS WIRE)–#avedro–Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has begun selling Photrexa Viscous® (riboflavin 5-‘phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System to key military hospitals around the country. Fort Belvoir Hospital, located in Fort Belvoir, VA, made history on November 21st to become the first military facility in the country to perform FDA-approved corneal cross-li
IACTA Pharmaceuticals Licenses NM133 from Nanomerics for Treatment of Dry Eye
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–IACTA Pharmaceuticals has acquired the North American rights to develop and commercialize NM133, an investigational medicine designed to help treat dry eye from its developer, Nanomerics, Ltd.
Second Sight Medical Products, Inc. Announces Rights Offering
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (Nasdaq:EYES) (“Second Sight” or “the Company”), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind patients, today announ…
Company Profile for EYENOSTICS
–(BUSINESS WIRE)–Eyenostics is a Contract Research Organization (CRO) dedicated to research and analysis of ocular biomarkers for clinical and preclinical studies using Flow Cytometry and RT-qPCR methods. With its experienced team of employees, partners and a renowned consultant, Eyenostics’ ambition is to become a preferred business partner for big pharmaceutical companies and biotechnology companies looking for new, relevant data for their ophthalmology studies. Eyenostics’ strength lies in
Acucela Receives Orphan Drug Designation from the FDA for the Treatment of Stargardt Disease
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) that specializes in identifying and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, announced today that the FDA (U.S. Food and Drug Administration) granted orphan drug designation to Acucela’s leading drug candidate emixustat hydrochloride (“emixustat”) for the tr
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Lucentis® (ranibizumab injection) 0.5 mg for the treatment of patients with myopic choroidal neovascularization (mCNV), a complication of severe near-sightedness that can lead to blindness. Lucentis is the first FDA-approved anti-vascular endothelial growth factor (VEGF) therapy to treat mCNV in the U.S.
Novaliq veröffentlicht positive Topline-Ergebnisse der klinischen Phase-II-Studie zur Evaluierung der Verabreichung von CyclASol® für Erwachsene mit mittlerem bis schwerem Trockene-Augen-Syndrom
HEIDELBERG, Deutschland–(BUSINESS WIRE)–Novaliq GmbH, ein Spezialpharma-Unternehmen mit disruptiver Dosierungstechnologie-Plattform, die schwer lösliche Wirkstoffe in wirksame Therapeutika zur Anwednung in der Ophthalmologie transformiert, veröffentlichte heute positive Ergebnisse einer Phase-II-Studie zur Evaluierung von CyclASol®, einer klaren, konservierungsmittelfreien „Cyclosporin A”-Lösung. Für die Studie wurden 207 Patienten mit mittlerem bis schwerem Trockene-Augen-Syndrom rekrutiert.
Riassunto: Novaliq annuncia importanti risultati positivi dello studio clinico di fase 2 mirato alla valutazione di CyclASol® negli adulti affetti da secchezza oculare da moderata a grave
HEIDELBERG, Germania–(BUSINESS WIRE)–Novaliq GmbH, società farmaceutica con una piattaforma di distribuzione di farmaci totalmente innovativa in grado di trasformare medicinali scarsamente solubili in terapie oftalmiche efficaci, ha oggi annunciato i risultati positivi dello studio clinico di fase 2 per la valutazione di CyclASol®, una soluzione di ciclosporina A, trasparente e senza conservanti, su 207 pazienti affetti da secchezza oculare (DED) da moderata a grave. CyclASol ha dimostrato un
Novaliq annonce des premiers résultats positifs de l’essai clinique de Phase 2 évaluant l’utilisation de CyclASol® chez les adultes qui souffrent d’une sécheresse oculaire modérée à sévère
HEIDELBERG, Allemagne–(BUSINESS WIRE)–Novaliq GmbH, société pharmaceutique de spécialité qui possède une plateforme d’administration de médicaments d’avant-garde, transformant des médicaments peu solubles en produits ophtalmologiques efficaces, a annoncé aujourd’hui avoir obtenu des résultats positifs de Phase 2 dans le cadre de l’évaluation de CyclASol®, solution à base de cyclosporine A transparente et sans agents de conservation, auprès de 207 patients souffrant d’une sécheresse oculaire m
Argus Vision Enters Partnership with PogoTec
LAS VEGAS–(BUSINESS WIRE)–January 4, 2017 – Taiwan-based Argus Vision today announced a strategic partnership with PogoTec to manufacture a new line of sun wear equipped with the PogoTrack™ wearable technology platform.
3M Completes Sale of its Safety Prescription Eyewear Business
ST. PAUL, Minn.–(BUSINESS WIRE)–3M announced today that it has completed the sale of its safety prescription eyewear business to HOYA Vision Care, a global leader in the eyeglass lens industry. The safety prescription eyewear business provides a comprehensive line of frames, prescription lenses, and premium coating options in a custom-made solution. The business has annual global sales of approximately $45 million. The safety prescription eyewear business was part of 3M’s Personal Safety Divi
RightEye vision performance assessments to be conducted at MLB and USA Baseball’s Prospect Development Pipeline events
WASHINGTON–(BUSINESS WIRE)–#CES–RightEye selected to provide baseline performance vision screenings for elite amateur baseball players at all MLB and USA Baseball Prospect Development Pipeline events.
BioTime and Subsidiary Cell Cure Neurosciences Establish Innovative Cell Therapy Manufacturing Center in Jerusalem, Israel
ALAMEDA, Calif. & JERUSALEM–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX and TASE: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, and its majority-owned subsidiary, Cell Cure Neurosciences Ltd, today dedicated a new, 800 square meter (8,600 square feet), state-of-the-art, cGMP manufacturing center located in the Jerusalem Bio Park on the campus of Hadassah University Hospital in Jerusalem. The new manufacturing center, in
Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma
LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced top-line results of MATrX-1, the first pivotal Phase 3 trial of trabodenoson for glaucoma.
Eyes as a Window to Your Health: RightEye Unveils New Assessments for Healthcare and Vision Performance at CES 2017
LAS VEGAS & WASHINGTON–(BUSINESS WIRE)–#CES–RightEye to unveil new assessments for healthcare and vision performance at CES 2017, where it will exhibit at Unveiled in booth 118, and at CES in booth 43035 in the Sands Convention Center.
Diabetic Macular Edema Market: By Type, Treatment Categories & Geography – With Forecast (2016-2021) – Research and Markets
DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Diabetic Macular Edema Market – With Forecast (2016-2021)” report to their offering. Diabetic Macular Edema (DME) is defined as an accumulation of fluid in the macula of t…
Glaukos Announces Participation in J.P. Morgan Healthcare Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, …
Ultra-Small Nanocavity Advances Technology for Secure Quantum-Based Data Encryption
WASHINGTON–(BUSINESS WIRE)–#OSA_OMEx–Researchers have developed a new type of light-enhancing optical cavity could help propel quantum-based encryption and a truly secure and future-proofed network.